A115180 Stock Overview
A biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Qurient Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩3,550.00 |
52 Week High | ₩8,269.23 |
52 Week Low | ₩2,361.54 |
Beta | 0.69 |
11 Month Change | -12.35% |
3 Month Change | -24.47% |
1 Year Change | -50.59% |
33 Year Change | n/a |
5 Year Change | -78.38% |
Change since IPO | -88.17% |
Recent News & Updates
Recent updates
Shareholder Returns
A115180 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -4.7% | -1.1% | 0.2% |
1Y | -50.6% | 17.7% | 7.1% |
Return vs Industry: A115180 underperformed the KR Biotechs industry which returned 17.7% over the past year.
Return vs Market: A115180 underperformed the KR Market which returned 7.1% over the past year.
Price Volatility
A115180 volatility | |
---|---|
A115180 Average Weekly Movement | 5.3% |
Biotechs Industry Average Movement | 7.5% |
Market Average Movement | 5.0% |
10% most volatile stocks in KR Market | 11.1% |
10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A115180's share price has been volatile over the past 3 months.
Volatility Over Time: A115180's weekly volatility has decreased from 13% to 5% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2008 | 33 | Ki-Yean Nam | www.qurient.com |
Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of solid tumors; and Q901, a selective CDK7 inhibitor, is under Phase I stage for treating solid tumors.
Qurient Co., Ltd. Fundamentals Summary
A115180 fundamental statistics | |
---|---|
Market cap | ₩117.13b |
Earnings (TTM) | -₩19.84b |
Revenue (TTM) | ₩8.99b |
13.0x
P/S Ratio-5.9x
P/E RatioIs A115180 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A115180 income statement (TTM) | |
---|---|
Revenue | ₩8.99b |
Cost of Revenue | ₩7.28b |
Gross Profit | ₩1.72b |
Other Expenses | ₩21.56b |
Earnings | -₩19.84b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -601.24 |
Gross Margin | 19.11% |
Net Profit Margin | -220.55% |
Debt/Equity Ratio | 0% |
How did A115180 perform over the long term?
See historical performance and comparison